製品番号: HY-N0790

Lupeol

(別名: Clerodol; Monogynol B; Fagarasterol)

6 Cited Publications

カスタマーレビュー

Based on 6 publication(s) in Google Scholar

Lupeol (Clerodol; Monogynol B; Fagarasterol) is an active pentacyclic triterpenoid, has anti-oxidant, anti-mutagenic, anti-tumor and anti-inflammatory activity. Lupeol is a potent androgen receptor (AR) inhibitor and can be used for cancer research, especially prostate cancer of androgen-dependent phenotype (ADPC) and castration resistant phenotype (CRPC).

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.0%
CAS 番号: 545-47-1
分子式: C₃₀H₅₀O
分子量:426.72

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Lupeol 構造式

CAS 番号: 545-47-1

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (6)
溶剤 & 溶解度
- 体外
- 体内
プロトコル
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

Androgen receptor^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	>10 μM Compound: 21	Cytotoxicity against human A2780 cells after 96 hrs by MTT assay Cytotoxicity against human A2780 cells after 96 hrs by MTT assay	[PMID: 24467317]
A2780	IC₅₀	>=20 μg/mL Compound: 4	Cytotoxicity against human A2780 cells Cytotoxicity against human A2780 cells	[PMID: 12662105]
A2780	IC₅₀	16.2 μg/mL Compound: 7	Cytotoxicity against human A2780 cells Cytotoxicity against human A2780 cells	[PMID: 12193040]
A2780	IC₅₀	26.4 μg/mL Compound: Lupeol	Cytotoxicity against human A2780 cells Cytotoxicity against human A2780 cells	[PMID: 15165160]
A549	IC₅₀	>10 μM Compound: 21	Cytotoxicity against human A549 cells after 96 hrs by MTT assay Cytotoxicity against human A549 cells after 96 hrs by MTT assay	[PMID: 24467317]
A549	IC₅₀	>20 μg/mL Compound: Lupeol	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21106454]
A549	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human A549 cells by resazurin reduction test Cytotoxicity against human A549 cells by resazurin reduction test	[PMID: 19285391]
A549	IC₅₀	25.18 μM Compound: Lupeol	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31784199]
B16	ED₅₀	9.9 μM Compound: 1	Induction of melanogenesis in mouse B16 2F2 cells assessed as intracellular melanin content after 3 days Induction of melanogenesis in mouse B16 2F2 cells assessed as intracellular melanin content after 3 days	[PMID: 12027734]
B16	IC₅₀	38 μM Compound: 1	Growth inhibition of mouse B16 2F2 cells after 3 days Growth inhibition of mouse B16 2F2 cells after 3 days	[PMID: 12027734]
Bel-7402	IC₅₀	>10 μM Compound: 21	Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay	[PMID: 24467317]
BGC-823	IC₅₀	>10 μM Compound: 21	Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay	[PMID: 24467317]
BGC-823	IC₅₀	>50 μM Compound: 3	Cytotoxicity against human BGC-823 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human BGC-823 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 37336771]
BHY	IC₅₀	25.18 μM Compound: Lupeol	Antiproliferative activity against human BHY cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human BHY cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31784199]
BV-2	IC₅₀	>10 μM Compound: 21	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 24467317]
BV-2	IC₅₀	>100 μM Compound: 35	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay	[PMID: 28911817]
Ca9-22	IC₅₀	16.78 μg/mL Compound: Lupeol	Cytotoxicity against human Ca9-22 cells by MTT assay Cytotoxicity against human Ca9-22 cells by MTT assay	[PMID: 21106454]
Calu-1	IC₅₀	>100 μM Compound: 5	Inhibition of human Calu1 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting Inhibition of human Calu1 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting	[PMID: 11374975]
COLO 205	IC₅₀	25.18 μM Compound: Lupeol	Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31784199]
DLD-1	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human DLD1 cells by resazurin reduction test Cytotoxicity against human DLD1 cells by resazurin reduction test	[PMID: 19285391]
HCT-116	IC₅₀	>50 μM Compound: 3	Cytotoxicity against human HCT-116 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 37336771]
HCT-8	IC₅₀	>10 μM Compound: 21	Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay	[PMID: 24467317]
HeLa	IC₅₀	>10 μg/mL Compound: lupeol	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 16038541]
HeLa	IC₅₀	>100 μM Compound: 5	Inhibition of human HeLa cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting Inhibition of human HeLa cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting	[PMID: 11374975]
HeLa	IC₅₀	>50 μM Compound: 5	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 19447618]
Hep 3B2	IC₅₀	18.83 μg/mL Compound: Lupeol	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 21106454]
HEp-2	IC₅₀	>10 μg/mL Compound: lupeol	Cytotoxicity against human Hep2 cells after 48 hrs by MTT assay Cytotoxicity against human Hep2 cells after 48 hrs by MTT assay	[PMID: 16038541]
HepG2	IC₅₀	>50 μM Compound: 3	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 37336771]
HepG2	IC₅₀	19.78 μg/mL Compound: Lupeol	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 21106454]
HUVEC	ED₅₀	>5 μg/mL Compound: lupeol	Cytotoxicity against human HUVEC Cytotoxicity against human HUVEC	[PMID: 15270571]
J774	IC₅₀	>234.3 μM Compound: 3	Cytotoxicity against mouse J774 cells by alamar blue assay Cytotoxicity against mouse J774 cells by alamar blue assay	[PMID: 17637068]
J774.A1	IC₅₀	34.5 μM Compound: 1, Lupeol	Antiinflammatory activity in mouse J774A1 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS challenge measured after 24 hrs by Griess method Antiinflammatory activity in mouse J774A1 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS challenge measured after 24 hrs by Griess method	[PMID: 24909081]
K562	IC₅₀	>100 μM Compound: 5	Inhibition of human K562 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting Inhibition of human K562 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting	[PMID: 11374975]
K562	IC₅₀	82.8 μg/mL Compound: Lupeol	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 2 days by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 2 days by MTT assay	[PMID: 32527555]
KB	ED₅₀	>20 μg/mL Compound: 17	Cytotoxicity against human epidermoid carcinoma of the mouth (KB) cell line. Cytotoxicity against human epidermoid carcinoma of the mouth (KB) cell line.	[PMID: 9873420]
KB	ED₅₀	>5 μg/mL Compound: lupeol	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 15270571]
LNCaP	ED₅₀	>5 μg/mL Compound: lupeol	Cytotoxicity against human LNCAP cells Cytotoxicity against human LNCAP cells	[PMID: 15270571]
Lu1	ED₅₀	>5 μg/mL Compound: lupeol	Cytotoxicity against human Lu1 cells Cytotoxicity against human Lu1 cells	[PMID: 15270571]
MCF7	IC₅₀	>20 μg/mL Compound: Lupeol	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 21106454]
MCF7	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human MCF7 cells by resazurin reduction test Cytotoxicity against human MCF7 cells by resazurin reduction test	[PMID: 19285391]
MCF7	IC₅₀	>50 μM Compound: 5	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 19447618]
MCF7	IC₅₀	25.18 μM Compound: Lupeol	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31784199]
MDA-MB-231	EC₅₀	208.9 μM Compound: Lupeol	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 28112509]
MDA-MB-231	IC₅₀	>20 μg/mL Compound: Lupeol	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 21106454]
MIA PaCa-2	IC₅₀	25.18 μM Compound: Lupeol	Antiproliferative activity against human MIAPaCa2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MIAPaCa2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31784199]
Neutrophil	IC₅₀	11.35 μg/mL Compound: 1	Immunomodulatory activity in neutrophils assessed as decrease in oxidative burst after 30 min by luminol-enhanced chemiluminescence assay Immunomodulatory activity in neutrophils assessed as decrease in oxidative burst after 30 min by luminol-enhanced chemiluminescence assay	10.1007/s00044-012-0183-y
PANC-1	IC₅₀	>50 μM Compound: 3	Cytotoxicity against human PANC-1 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human PANC-1 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 37336771]
PBL	IC₅₀	13.16 μg/mL Compound: 1	Antiproliferative activity against PHA-induced Homo sapiens (human) peripheral blood lymphocytes assessed as inhibition of [3H]-thymidine incorporation after 72 hr by beta-scintillation counting analysis Antiproliferative activity against PHA-induced Homo sapiens (human) peripheral blood lymphocytes assessed as inhibition of [3H]-thymidine incorporation after 72 hr by beta-scintillation counting analysis	10.1007/s00044-012-0183-y
PC-3	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human PC3 cells by resazurin reduction test Cytotoxicity against human PC3 cells by resazurin reduction test	[PMID: 19285391]
PC-9	IC₅₀	>50 μM Compound: 3	Cytotoxicity against human PC-9 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human PC-9 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 37336771]
Raji	IC₅₀	>100 μM Compound: 5	Inhibition of human Raji cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting Inhibition of human Raji cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting	[PMID: 11374975]
RAW264.7	IC₅₀	>0.4 μM Compound: 20(29)-lupen-3-ol	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide release after 24 hrs Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide release after 24 hrs	[PMID: 20192236]
RAW264.7	IC₅₀	37.3 μM Compound: 1, Lupeol	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS challenge measured after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS challenge measured after 24 hrs by Griess method	[PMID: 24909081]
RAW264.7	IC₅₀	37.3 μM Compound: Lupeol	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38107170]
SK-MEL-1	IC₅₀	>50 μM Compound: 5	Cytotoxicity against human SK-MEL-1 cells by MTT assay Cytotoxicity against human SK-MEL-1 cells by MTT assay	[PMID: 19447618]
SK-MEL-2	ED₅₀	17.6 μg/mL Compound: 17	Cytotoxicity against cultured human melanoma (MEL-2) cell line. Cytotoxicity against cultured human melanoma (MEL-2) cell line.	[PMID: 9873420]
Vero	IC₅₀	>10 μg/mL Compound: lupeol	Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay	[PMID: 16038541]
Vero	IC₅₀	>100 μM Compound: 5	Inhibition of african green monkey Vero cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting Inhibition of african green monkey Vero cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting	[PMID: 11374975]
WISH	IC₅₀	>100 μM Compound: 5	Inhibition of human WISH cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting Inhibition of human WISH cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting	[PMID: 11374975]

体外実験

Lupeol, an effective AR inhibitor, can be developed as a potential agent to treat human prostate cancer (CaP). Lupeol (10-50 μM) treatment for 48 h results in a dose-dependent growth inhibition of androgen-dependent phenotype (ADPC) cells viz., LAPC4 and LNCaP cells with an IC₅₀ of 15.9 and 17.3 μM, respectively. Lupeol also inhibits the growth of 22Rν_1 with an IC₅₀ of 19.1 μM. Further, Lupeol inhibits the growth of C4-2b cells with an IC₅₀ of 25 μM. Lupeol has the potential to inhibit the growth of CaP cells of both ADPC and CRPC phenotype. Androgens by activating AR are known to drive the growth of CaP cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Lupeol is an effective agent that has the potential to inhibit the tumorigenicity of CaP cells in vivo. At the conclusion of the study on day 56, the total circulating serum-PSA levels (secreted by the implanted tumor cells) are measured. At 56thday post-implantation, PSA levels are observed between 11.95-12.79 ng/mL in control animals with LNCaP-tumors and C4-2b-tumors, respectively. However, Lupeol-treated counterpart animals exhibits reduced serum-PSA levels in a range of 4.25-7.09 ng/mL. Tumor tissues of animals receiving Lupeol treatment exhibits reduced serum-PSA levels as compared to control^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 545-47-1
性状 Solid
分子量 426.72
分子式 C₃₀H₅₀O
Color White to off-white
SMILES

C[C@]1([C@@]2(CC[C@@]3([H])C4(C)C)C)[C@@](CC[C@]2([H])[C@]3(CC[C@@H]4O)C)([H])[C@]([C@@H]5C(C)=C)([H])[C@](C)(CC5)CC1
別名

Clerodol; Monogynol B; Fagarasterol
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Plants
- other families
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (6)

All Histological Imaging/StainingWBRT-PCRIF

Sort by:

Journal Impact Factor

Phytomedicine

Lupeol alleviates autoimmune myocarditis by suppressing macrophage pyroptosis and polarization via PPARα/LACC1/NF-κB signaling pathway. [Abstract]

2024 Jan:123:155193. PMID: 37976692

Lupeol purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Jan:123:155193. [Abstract]

Representative images of hematoxylin and eosin staining of myocardial sections and histoscore of inflammation 21 days after the first immunization treated with Lupeol (Lup) (25, 50 mg/kg, i.g.).

Lupeol purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Jan:123:155193. [Abstract]

The expression levels of pyroptosis-related proteins in THP-1-derived macrophages and BMDMs (100 ng/mL LPS, 3 h; ATP 5 μM, 1 h; with or without Lup (5, 10, 20 μM) pretreatment) measured by Western blotting.

Lupeol purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Jan:123:155193. [Abstract]

The cardiac mRNA expressions of pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) analyzed by qPCR treated with Lupeol (Lup) (25, 50 mg/kg, i.g.).

Lupeol purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Jan:123:155193. [Abstract]

Representative coimmunostaining of iNOS (green) and CD11b (red) treated with Lupeol (Lup) (25, 50 mg/kg, i.g.).
ISME J

Akkermansia muciniphila exacerbates acute radiation-induced intestinal injury by depleting mucin and enhancing inflammation. [Abstract]

2025 Jan 2;19(1):wraf084. PMID: 40305678
Food Funct

Lupeol inhibits the proliferation and migration of MDA-MB-231 breast cancer cells via a novel crosstalk mechanism between autophagy and the EMT. [Abstract]

2022 May 10;13(9):4967-4976. PMID: 35448900
Tissue Cell

Lupeol induces apoptosis of glioma cells via governing ubiquitination-mediated SPARC turnover. [Abstract]

2025 Dec:97:103039. PMID: 40779907
Immunopharmacol Immunotoxicol

Lupeol triggers oxidative stress, ferroptosis, apoptosis and restrains inflammation in nasopharyngeal carcinoma via AMPK/NF-κB pathway. [Abstract]

2022 Aug;44(4):621-631. PMID: 35486494
SSRN

2026 Apr 11.

溶剤 & 溶解度

体外:

Ethanol : 14.29 mg/mL (33.49 mM; ultrasonic and warming and heat to 60°C)

DMSO : 2 mg/mL (4.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3435 mL

11.7173 mL

23.4346 mL

5 mM

0.4687 mL

2.3435 mL

4.6869 mL

10 mM

0.2343 mL

1.1717 mL

2.3435 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 1.43 mg/mL (3.35 mM); Clear solution

This protocol yields a clear solution of ≥ 1.43 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (14.3 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Corn Oil

Solubility: 20 mg/mL (46.87 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

プロトコル

Cell Assay^[1]

LAPC4 (wild-functional AR/ADPC); LNCaP (mutant-functional AR/ADPC); 22Rν1 (mutant-functional AR/androgen-independent but responsive); C4-2b cells (mutant-functional AR/CRPC) and PC-3 and DU-145 (lack of endogenous AR) are grown under standard cell culture conditions at 37°C and 5% CO₂ environment. The cells (60-70% confluent) are treated with Lupeol (10-50 μM) for 48 h in complete growth medium. For combination set of experiments, cells are treated with either agonistic androgen-analogue R1881 (1 nM), or antagonist Bicalutamide (10 μM), and/or combination (R1881+Lupeol) for 48 h. After incubation for specified times at 37°C, MTT assay is performed. For sensitization studies, hormone refractory C4-2b cells are treated with Lupeol for 24 h. After 24 h, cells are incubated with Bicalutamide (10 μM) for further 24 h. Cells are assessed for viability^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice^[1]
Tumor studies are conducted in athymic nude mice and two cohorts of animals are created. 3×10⁶ of cells are injected subcutaneously in the right flanks of each mouse. Each cohort receive a specific cell type either LNCaP or C4-2b. One week post-implantation, twenty mice (with visible tumors) in each cohort are randomly divided into two groups, with 10 animals in each group. The first group of animals receive intraperitoneal (i.p.) administration of corn oil (100 μL) and served as control. The second group of animals receive i.p. administration of Lupeol (40 mg/kg in 100 μL of corn oil) three times/week. Body weights and tumor volumes are recorded. All animals of group 1 and group 2 are sacrificed when tumors cross a pre-set endpoint volume of 1,000 mm³.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (282 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Siddique HR, et al. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy. Clin Cancer Res. 2011 Aug 15;17(16):5379-91. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / Ethanol	1 mM	2.3435 mL	11.7173 mL	23.4346 mL	58.5864 mL
Ethanol	5 mM	0.4687 mL	2.3435 mL	4.6869 mL	11.7173 mL
	10 mM	0.2343 mL	1.1717 mL	2.3435 mL	5.8586 mL
	15 mM	0.1562 mL	0.7812 mL	1.5623 mL	3.9058 mL
	20 mM	0.1172 mL	0.5859 mL	1.1717 mL	2.9293 mL
	25 mM	0.0937 mL	0.4687 mL	0.9374 mL	2.3435 mL
	30 mM	0.0781 mL	0.3906 mL	0.7812 mL	1.9529 mL

Lupeol

6 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Lupeol

Apoptosis Compound Library

Natural Product Library

Anti-Cancer Compound Library

Lipid Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Traditional Chinese Medicine Active Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Nuclear Receptor Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Cell Death Library

Anti-Drug-Resistant Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

RNA Binding Bioactive Compound Library

MedChemExpress（MCE）の使用を引用している文献 Lupeol

生物活性

化学情報

Publications (6)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Lupeol 関連分類

HY-N0790 関連分類